Sildenafil (Generic) Pregnancy and Lactation Safety

How Sildenafil Works: PDE5 Inhibition and Vascular Smooth Muscle

Sildenafil inhibits phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. By blocking PDE5, sildenafil allows cGMP to accumulate, promoting vasodilation in tissues where nitric oxide signaling is active. This mechanism underpins its approved uses in erectile dysfunction and pulmonary arterial hypertension.

The original proof of efficacy for ED came from Goldstein et al. (NEJM 1998), a multicenter trial of 532 men that demonstrated dose-dependent improvements in erectile function scores across the 25-100 mg range 1. Sildenafil reaches peak plasma concentration within 30 to 120 minutes after oral dosing. Its plasma half-life is 3 to 5 hours. Hepatic metabolism occurs primarily via CYP3A4 and, to a lesser extent, CYP2C9, producing the active metabolite N-desmethylsildenafil 2.

Why does the mechanism matter for pregnancy? The placenta relies on nitric oxide-mediated vasodilation for adequate uteroplacental perfusion. Researchers hypothesized that PDE5 inhibition could improve blood flow to a growth-restricted fetus. That hypothesis drove a decade of clinical investigation. The results were not what investigators expected.

FDA Labeling and Regulatory Status in Pregnancy

No sildenafil product carries an FDA-approved indication for use during pregnancy. Under the Pregnancy and Lactation Labeling Rule (PLLR), which replaced the older letter-category system (A, B, C, D, X) in 2015, sildenafil labeling provides a narrative risk summary rather than a single letter grade 2.

The FDA label for Revatio (sildenafil 20 mg, approved for pulmonary arterial hypertension) states that animal reproduction studies in rats and rabbits at doses producing exposures approximately 20 and 40 times the recommended human dose revealed no evidence of teratogenicity 3. Rats showed reduced pup survival and birth weight at maternally toxic doses only. No adequate, well-controlled studies existed in pregnant women at the time of labeling.

The European Medicines Agency (EMA) echoes this position. Its product information for sildenafil states: "Sildenafil should not be used during pregnancy unless strictly necessary" 4. Both agencies classify sildenafil as a drug with insufficient human gestational data to define a clear risk profile.

The STRIDER Trials: The Central Evidence Base

The Sildenafil Therapy In Dismal prognosis Early-onset fetal Growth Restriction (STRIDER) consortium represents the largest controlled investigation of sildenafil in pregnancy. Multiple parallel randomized controlled trials enrolled women with severe early-onset fetal growth restriction (FGR) diagnosed before 30 weeks of gestation across the UK, Ireland, the Netherlands, Australia, New Zealand, and Canada.

The rationale was straightforward. Severe early-onset FGR carries perinatal mortality rates exceeding 30% in some cohorts. No effective pharmacotherapy exists. Sildenafil, by relaxing uterine artery smooth muscle, might improve placental perfusion enough to extend pregnancy duration and increase birthweight.

Results told a different story. The Dutch STRIDER arm (N=216) was halted prematurely in July 2018 after a Data Safety Monitoring Board review. In the sildenafil group, 19 neonates died compared with 9 in the placebo group. Eleven of those sildenafil-exposed neonatal deaths involved persistent pulmonary hypertension of the newborn (PPHN), compared with 3 PPHN-related deaths in controls 4. This signal was alarming. The trial's lead investigator, Dr. Wessel Ganzevoort of Amsterdam UMC, stated: "We found no benefit on any of our outcomes, and the signal of increased neonatal pulmonary hypertension prompted us to stop the trial" 4.

The UK and Ireland STRIDER arm (N=135) likewise found no significant difference in the primary outcome of abdominal circumference growth velocity. Mean birthweight did not differ between groups (sildenafil 598 g vs. placebo 590 g, P=0.77). Perinatal survival was comparable 5.

An individual participant data meta-analysis by Pels et al. (2020) pooled 329 participants across STRIDER sites and confirmed no benefit of sildenafil 75 mg daily on prolongation of pregnancy (hazard ratio 1.09 to 95% CI 0.82-1.44) or on birthweight centile 6. The pooled analysis could not definitively confirm or exclude the PPHN signal due to limited power, but the absence of any efficacy signal extinguished the clinical rationale for continued investigation of this specific indication.

Sildenafil for Preeclampsia: A Separate Evidence Thread

Investigators have also explored sildenafil for preeclampsia prevention and treatment. The biological logic is similar: deficient nitric oxide signaling contributes to the endothelial dysfunction that characterizes preeclampsia. PDE5 inhibition might offset that deficit.

Samangaya et al. (2009) conducted a pilot double-blind RCT of sildenafil 20 mg three times daily in 35 women with early-onset preeclampsia between 24 and 34 weeks. Mean arterial pressure fell by 4.7 mmHg more in the sildenafil group than in controls. No serious adverse maternal or fetal events occurred in this small cohort 7.

A Cochrane systematic review on interventions for treating preeclampsia (2018) noted that evidence for PDE5 inhibitors remained insufficient to guide practice, with total enrolled participants across all trials numbering fewer than 200 8. The review's authors concluded that "large, adequately powered, randomised trials are needed before PDE5 inhibitors can be recommended for preeclampsia management."

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Gestational Hypertension and Preeclampsia does not include sildenafil among recommended interventions 9. Standard first-line management remains magnesium sulfate for seizure prophylaxis and antihypertensives (labetalol, nifedipine, hydralazine) for severe-range blood pressures, with delivery as the definitive treatment.

Sildenafil in Pulmonary Arterial Hypertension During Pregnancy

Pulmonary arterial hypertension (PAH) in pregnancy carries maternal mortality rates historically cited at 30-56%, though contemporary registries suggest lower figures with modern management 10. Sildenafil (as Revatio, 20 mg three times daily) is FDA-approved for PAH in non-pregnant adults and has been used off-label in pregnant patients with PAH as part of multimodal therapy.

Case series describe outcomes in pregnant women with PAH treated with sildenafil alongside prostacyclin analogs, endothelin receptor antagonists (though bosentan is teratogenic and must be stopped), and supportive care. A 2015 systematic review by Bédard et al. found maternal mortality of approximately 17% across 382 pregnancies complicated by PAH from 1997 to 2013, with sildenafil used in a subset 10. The data are observational and confounded by indication.

The Endocrine Society's clinical practice guidelines do not specifically address sildenafil use during pregnancy for PAH; this falls under cardiology and maternal-fetal medicine specialty guidance. The European Society of Cardiology (ESC) 2018 guidelines on cardiovascular diseases in pregnancy advise that PAH patients should be counseled against pregnancy entirely. When pregnancy does occur, management requires a multidisciplinary team, and PDE5 inhibitors represent one component of a complex treatment regimen rather than a standalone intervention 10.

Lactation Safety: What the Evidence Shows

Data on sildenafil transfer into human breast milk are scarce. LactMed, the NIH's peer-reviewed lactation pharmacology database, reports no published measurements of sildenafil concentrations in breast milk as of the most recent review 11.

Pharmacokinetic properties suggest limited transfer. Sildenafil is 96% protein-bound, has a molecular weight of 475 Da (borderline for passive diffusion into milk), and carries a relatively short half-life of 3 to 5 hours 2. Drugs with high protein binding and short half-lives tend to achieve low milk-to-plasma ratios. The active metabolite, N-desmethylsildenafil, is approximately 50% as potent as the parent compound and also highly protein-bound.

No case reports document adverse effects in breastfed infants exposed to maternal sildenafil. This absence of signal is weakly reassuring but cannot substitute for measured concentrations and formal infant safety data. LactMed recommends that "because of the lack of data on the use of sildenafil during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant" 11.

For lactating women taking sildenafil 20 mg three times daily for PAH (where discontinuation poses genuine maternal risk), clinicians typically continue therapy while monitoring the infant for hypotension, irritability, or poor feeding. On-demand use at higher ED doses (50-100 mg) is a different scenario: the drug is taken intermittently, and timing a single dose to minimize infant exposure (taking sildenafil immediately after a feeding, then avoiding nursing for 4-5 hours) could reduce transfer.

Risk-Benefit Considerations for Prescribers

The risk calculus differs depending on indication, dose, and trimester. Three scenarios recur in clinical practice.

Scenario 1: A male partner takes sildenafil for ED. Sildenafil at standard ED doses (25-100 mg) is present in seminal fluid at concentrations roughly 10 to 12 times lower than in plasma 12. No evidence suggests that seminal sildenafil exposure affects fertilization, implantation, or embryonic development. This is not a clinical concern.

Scenario 2: A pregnant woman with severe PAH. Continuation of sildenafil (typically 20 mg three times daily) may be reasonable when the maternal mortality risk from untreated or undertreated PAH outweighs the uncertain fetal risks. STRIDER data do not directly apply here because the population, dose rationale, and outcomes of interest are different. Joint decision-making with maternal-fetal medicine and cardiology teams is the standard of care.

Scenario 3: Off-label use for FGR or preeclampsia. After the STRIDER consortium results, no professional society recommends sildenafil for these indications outside of research protocols. The Fetal Medicine Foundation, ACOG, and the Royal College of Obstetricians and Gynaecologists (RCOG) have not incorporated sildenafil into any FGR management guideline 9.

Animal Reproductive Toxicology Data

Preclinical studies provide context for the human findings. In rat fertility and early embryonic development studies, sildenafil at 60 mg/kg/day (producing systemic exposures approximately 25 times the human AUC at 100 mg) caused no effects on mating, fertility, or early development 3.

Embryo-fetal development studies in rats and rabbits at doses up to 200 mg/kg/day and 40 mg/kg/day, respectively, showed no teratogenic effects. Reduced fetal body weight occurred in rats only at doses that also produced maternal toxicity (200 mg/kg/day). Pre- and postnatal development studies in rats showed reduced pup body weight and survival at 60 mg/kg/day 3.

These animal data are reassuring for gross teratogenicity but do not address the PPHN signal seen in STRIDER. The mechanism for that signal, if real, may involve fetal pulmonary vascular remodeling in response to chronic PDE5 inhibition during the canalicular and saccular stages of lung development (roughly 16-36 weeks). This remains a hypothesis. Preclinical models of chronic in-utero PDE5 inhibition at human-equivalent exposures during late gestation have not been adequately studied.

Practical Guidance: What Clinicians Should Tell Patients

For women of reproductive age prescribed sildenafil (whether for PAH or off-label indications), contraception counseling is appropriate. If unplanned pregnancy occurs during sildenafil use at PAH doses, abrupt discontinuation is not advised; a managed transition under specialist guidance reduces the risk of PAH decompensation.

For male patients: sildenafil does not impair fertility and poses no known risk to a conception partner or developing embryo through seminal exposure 12.

For breastfeeding patients on sildenafil for PAH: continue therapy if maternal benefit outweighs theoretical infant risk, monitor the infant clinically, and document the shared decision in the chart. For on-demand ED use in a lactating individual, counsel on dose timing relative to nursing.

No clinical laboratory monitoring specific to sildenafil exposure is recommended for the neonate or breastfed infant in current guidelines.